AIM: aimimmuno.com P/S Multiple
Volatility for AIM ImmunoTech (AIM) is driven by the exclusivity of Ampligen RNA therapy for combating cancer and viruses. The company's price-to-sales ratio visualizes market demand, where 60.40 represents the current metric. While stability depends on grants and clinical trial outcomes, a critical reliance on a single product and external funding creates significant risks for the business model.
Analytical breakdowns for AIM ImmunoTech (AIM)
- current quotes and average value forecast:
- market capitalization information:
- balance sheet equity data:
- debt obligations and liquidity statistics:
- net income and valuation ratios data:
AIM - Company Net Income|Net Profit Forecast AIM ImmunoTech|AIM - Price to Earnings Ratio|Projected Price to Earnings Ratio AIM ImmunoTech, Inc.|AIM - Price/Earnings to Growth Multiple|Enterprise Value to Operating Income Before Depreciation Ratio AIM ImmunoTech|AIM - Operating profit EBITDA|Net earnings per one share for the last twelve months AIM ImmunoTech|AIM - Net earnings per share (EPS TTM)|Year-over-year net earnings per share growth for the last 12 months aimimmuno.com|AIM - Earnings growth in current year|Expected earnings per share trend next year AIM ImmunoTech
- total revenue and sales volume data:
Fundamental company analysis:AIM (AIM ImmunoTech, Inc.)
The P/S multiple determines the market value of one dollar of revenue, capturing the gap between market capitalization and actual cash inflows from sales. By analyzing the current P/S ratio, an investor assesses the monetization efficiency of AIM ImmunoTech biopharmaceutical developments, including the impact of laboratory ESG optimization and ethical standards on the business's market attractiveness and the growth rate of its fundamental value.
Competitors of AIM ImmunoTech
ARGX - Price to Sales|P/S Multiple BNTX (BioNTech)|P/S Multiple Abivax Pharma ABVX|ADMA Bio - P/S Multiple|Price-to-Revenue Coefficient Protagonist Corp PTGX|Immunovant, Inc. (IMVT) - Price-to-Revenue Ratio|Market Cap to Revenue kiniksa.com|Market Cap to Revenue GRFS|ADPT: Market Capitalization-to-Revenue Ratio|P/S Multiple CLDX|Price-to-Revenue Coefficient Aurinia Corp|Price-to-Revenue Ratio BioCryst BCRX|VERA - Market Cap to Revenue|DNTH - Price-to-Revenue Ratio|Pharvaris NV (PHVS) - Market Cap to Revenue|ABCL (AbCellera Biologics Inc) - Market Cap to Revenue|Tourmaline (TRML) - P/S Multiple|Price-to-Revenue Ratio Precigen, Inc.|Market Cap to Revenue Ratio PHAR (pharming.com)|Price-to-Revenue Ratio Nektar Therapeutics Inc. (NKTR)|UPB - Price to Sales|Zenas Biopharma, Inc. - Market Cap to Revenue|Market Cap to Sales Volume IMNM (Immunome Bio)|Gossamer Bio, Inc. - P/S Multiple|Price to Sales kalvista.com|SEPN: P/S Multiple|Market Cap to Revenue Pieris Pharma|SVRA (Savara Corp) - P/S Multiple|RIGL: Market Capitalization-to-Revenue Ratio|P/S Multiple ANAB|P/S Multiple astriatx.com (ATXS)|P/S Multiple ENGN (enGene)|Price-to-Revenue Coefficient RAPT Therapeutics Inc. (RAPT)|JBIO - Price-to-Revenue Ratio|Aclaris Therapeutics, Inc (ACRS) - Market Cap to Revenue|Kyverna Therapeutics (KYTX) - Price-to-Revenue Ratio|Price-to-Sales Ratio TLSA (tizianalifesciences.com)|CABA (Cabaletta Bio) - P/S Multiple|VTYX: Market Capitalization-to-Revenue Ratio|P/S Multiple THTX|P/S Multiple Avalo Therapeutics Inc (AVTX)|Price-to-Revenue Ratio Eledon Pharmaceuticals ELDN|Market Capitalization-to-Revenue Ratio AGEN|CLYM - Price-to-Revenue Ratio|Zura Bio Ltd (ZURA) - Market Cap to Revenue|ATYR: P/S Multiple|Adagene Inc. (ADAG) - P/S Multiple|Market Cap to Revenue IMA|STTK: Market Capitalization-to-Revenue Ratio|P/S Multiple EQ|Price-to-Revenue Coefficient connectbiopharm.com|Price-to-Revenue Ratio Immunic IMUX|ATRA - Market Cap to Revenue|IFRX - Price-to-Revenue Ratio|x4pharma.com (XFOR) - Market Cap to Revenue|ACET (adicetbio.com) - Market Cap to Revenue|Celularity (CELU) - P/S Multiple|Price-to-Revenue Ratio INmune Bio Corp|Market Cap to Revenue Ratio BRNS (Barinthus Biotherapeutics Corp)|P/S Multiple KZR|SABS - Price to Sales|P/S Multiple AKTX (Akari Therapeutics Plc)|P/S Multiple Enlivex Therapeutics Ltd ENLV|Q32 Bio Corp - P/S Multiple|Price-to-Revenue Coefficient GeoVax Corp GOVX|Edesa Biotech, Inc. (EDSA) - Price-to-Revenue Ratio|Market Cap to Revenue ibioinc.com|Market Cap to Revenue CARM|XTLB: Market Capitalization-to-Revenue Ratio|P/S Multiple BOLT|Price-to-Revenue Coefficient hcwbiologics.com|Price-to-Revenue Ratio Aptevo Therapeutics Inc. APVO|ADTX - Market Cap to Revenue|GRI - Price-to-Revenue Ratio|XORTX Therapeutics Inc (XRTX) - Market Cap to Revenue|HIND (ReShape Lifesciences) - Market Cap to Revenue|Revelation Biosciences Corp (REVB) - P/S Multiple|Price-to-Revenue Ratio Indaptus Therapeutics|Market Cap to Revenue Ratio SCNI (scinai.com)|Price-to-Revenue Ratio CalciMedica, Inc. (CALI)|AFMD - Price to Sales|Allakos - Market Cap to Revenue|Market Cap to Sales Volume HOOK (HOOKIPA Pharma, Inc.)|IGM Bio - P/S Multiple|Price to Sales iteostherapeutics.com|OCEA: P/S Multiple|Market Cap to Revenue TC BioPharm (Holdings) Plc|THRD (Third Harmonic Bio, Inc) - P/S Multiple
